Categories
Change Password!
Reset Password!
With the rapid onset of action, filgotinib presents
significant improvements in the condition of patients suffered from active
psoriatic arthritis.
Evident from the EQUATOR trial, “the psoriatic arthritis treatment with filgotinib shows considerable rectifications in psoriasis, enthesitis, and peripheral arthritis.” The trial involved a total of 191 patients with active moderate-to-severe psoriatic arthritis from 25 places in seven countries.
These patients showed no response against at least one csDMARD (one conventional synthetic disease-modifying anti-rheumatic drug) and the uptake of that DMARD was continued throughout the analysis, if the patients obtained this treatment for 12 weeks before screening. Afterwards, they were on a stable dose for approximately four weeks prior to baseline. Further, the patients obtaining 20% improvements in ACR20 (American College of Rheumatology response criteria) at week 16 was considered as the major endpoint of the analysis.
The major endpoint noticed
in 80% of patients from filgotinib group and 33% of placebo group. The most
common side effects that noticed in both groups were headache and
nasopharyngitis. There was one treatment-emergent adverse effect also found in
the patients of both groups. Regarding safety, no new data was detected.
Overall, this JAK1 inhibition shows significant better overall psoriatic
arthritis disease control.
The Lancet
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease et al.
Comments (0)